Kesimpta Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2020.
Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study. Poster presentation at: ACTRIMS; February 2020; West Palm Beach, FL.
Smith P, Kakarieka A, Wallstroem E. Ofatumumab is a fully human anti-CD20 antibody achieving potent B-cell depletion through binding a distinct epitope. Poster presentation at: ECTRIMS; September 2016; London, UK.
Hauser S. Efficacy and safety of ofatumumab versus teriflunomide in relapsing multiple sclerosis: results of the phase 3 ASCLEPIOS I and II trials. Oral presentation. ECTRIMS 2019.
Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis: analysis of no evidence of disease activity (NEDA-3) from ASCLEPIOS I and II trials. Eur J Neurol. 2020;27(S1).
J.-I.Kira, J. Nakahara, D.V.Sazonov, et al. Efficacy and safety of ofatumumab versus placebo in relapsing multiple sclerosis patients in Japan and Russia: Results from the Phase 2 APOLITOS study, ePoster presentation at: MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting; September 2020
Guthrie E. Multiple sclerosis: a primer and update. Adv Studies Pharm. 2007;4(11):313-317.
Osoegawa M, et al.: Mult Scler.; 15(2): 159-73. 2009.
Multiple Sclerosis International Federation.: Atlas of MS 2013
[Nandoskar A, et al. (2017)] Pharmacological aproaches to the Management of Secondary Progressive Mulitple Sclerosis. Drugs; 7 (8); 885-910.
[Strober L, et al, (2014)] Unemployment in multiple sclerosis (MS) : utility of the MS Functional Composite and cognitive testing. Mult Scler; 20(1):112-5.
[Naoshy S, et al. (2015)] The Impact of Increasing Multiple Sclerosis (MS) Severity Level on Employment and Caregiver Burden. Value Health 18(7) 722-9.